Fritextsökning
Artiklar per år
Innehållstyper
-
The life science strategy – what the industry wants
The process of updating the national life science strategy has begun at the government’s life science office. According to industry stakeholders, Sweden’s competitiveness, the accessibility of health data and the integration of innovation in healthcare are some of the points that are essential to review.
-
”We need compatibility“
Penilla Gunther, founder of Fokus Patient and chair of the European Patient Safety Foundation, hopes that the forthcoming life science strategy will focus on efficient and secure management of patient data and equal access to medicines.
-
“Life science is important on a personal level”
From the High Coast to the Government Offices. Jeanette Edblad is a native of Ångermanland, and since September last year, she has been Head and Coordinator of the Government’s Life Science Office.
-
From Valneva to the CEO position at NorthX – “I saw it as a great opportunity”
A new cell therapy for leukaemia, a vaccine in tablet form against cholera, and a proprietary mRNA line with the potential capacity to supply the entire Nordic region with vaccines during a future pandemic. These are some of the projects underway at NorthX Biologics – under the direction of new CEO Janet Hoogstraate.
-
CAR-T-terapi rekommenderas i tidigare stadium av cancer
CAR-T-behandlingen Carvykti bör kunna sättas in i ett tidigare sjukdomsskede än idag mot cancer i benmärgen. Det anser en expertkommitté vid den europeiska läkemedelsmyndigheten EMA.
-
To build trust, one must be able to say “I don’t know” – whether human or AI
Will AI strengthen or break down trust? It depends on whether we can understand and accept its limitations, and our own, writes Sarah Lidé in a column.
-
Första T-cellsterapin mot solida tumörer fick FDA-godkännande
För första gången har en T-cellsimmunterapi mot solida tumörer godkänts av den amerikanska läkemedelsmyndigheten FDA.
-
Samuel Lagercrantz: ”Drömmen blev en mardröm för life science-entreprenören”
En hyllad forskare och entreprenör i Västsverige tvingades lämna bolaget han själv grundat. Fallet har väckt stort intresse bland Life Science Swedens läsare. Samuel Lagercrantz, chefredaktör för Life Science Sweden, kommenterar fallet.
-
Anna Törner: “My quantified life”
“The expression ‘you can’t see the forest for the trees’ feels newly relevant in the context of wearables. One can easily get caught up in the idea that the more we measure, the more we know,” Anna Törner writes in a column.
-
Failed to read the fine print – lost his life’s work
A celebrated CEO and co-founder of a pioneering lab company one moment – the next, fired, kicked out and written out of the company’s history. This is the story of a Swedish entrepreneur who was going to raise US venture capital to strengthen his company but lost his life’s work instead.
-
Suing the company – for NOT developing a new HIV drug
Was Gilead putting a steady flow of profits from its cash cow ahead of developing a new and safer drug? According to a large number of US HIV patients in a legal case with an unusual twist, the answer is yes.
-
Svenskt CAR-T-bolag fyller på kassan
Elicera Therapeutics, som bland annat utvecklar CAR-T-terapier mot cancer, aviserar en nyemission som kan tillföra bolaget upp till 64 miljoner kronor.
-
Läste inte det finstilta – miste sitt livsverk
I ena stunden hyllad vd och medgrundare till ett banbrytande labbföretag – i nästa avskedad, utkastad och raderad ur bolagets historia. Här är historien om hur en svensk entreprenör skulle ta in amerikanskt riskkapital för att stärka företaget, men i stället blev av med sitt livsverk.
-
Major investment in women’s health – for a more equal healthcare system
”The regional differences need to decrease and the long-term supply of midwives and other professions needs to be secured,” write Acko Ankarberg Johansson and Désirée Pethrus (both Christian Democrats), in an opinion article.
-
EMA inleder säkerhetsöversyn av CAR-T-terapier
Den europeiska läkemedelsmyndigheten EMA har inlett en granskning av säkerheten hos CAR-T-terapier mot cancer och en eventuell koppling till uppkomst av sekundära cancersjukdomar.
-
Astra Zeneca förvärvar kinesiskt CAR-T-bolag
Astra Zeneca förvärvar kinesiska Gracell, som utvecklar en CAR-T-terapi mot blodcancer och autoimmuna sjukdomar.